NCT04983901 2026-04-06
PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN
M.D. Anderson Cancer Center
Phase 2 Completed
Clinical Trials
156 trialsNCT02494258 2026-04-02
A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders
Celgene
Phase 2 Completed
NCT05433090 2026-03-31
Inpatient SICP
University of Rochester
Phase NA Completed
NCT01315132 2026-03-19
A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies
Thomas Jefferson University
Phase 2 Completed
NCT02730299 2026-02-25
Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS
Gamida Cell ltd
Phase 3 Completed
NCT05371054 2026-02-23
Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT01203722 2026-02-19
Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT05005442 2026-02-19
A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT03159702 2026-01-27
Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation
Medical College of Wisconsin
Phase 2 Completed
NCT04294641 2026-01-23
Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT05063591 2026-01-15
BRUOG-407
Brown University
Phase NA Completed
NCT04307134 2025-12-31
Besponsa Post Marketing Surveillance Study
Pfizer
Completed
NCT01349101 2025-12-15
A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors
Thomas Jefferson University
Phase 2 Completed
NCT04620369 2025-12-03
Rose Geranium in Sesame Oil Nasal Spray for the Improvement of Nasal Vestibulitis Symptoms in Cancer Patients Receiving Chemotherapy
Mayo Clinic
Phase 3 Completed
NCT03136445 2025-10-28
TREATT
NHS Blood and Transplant
Phase 3 Completed
NCT04112810 2025-10-21
Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease
Medical College of Wisconsin
Phase 2 Completed
NCT03892967 2025-10-07
E2C2
Mayo Clinic
Phase NA Completed
NCT03680092 2025-10-02
Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation
University of California, San Diego
Phase 2 Completed
NCT05549232 2025-07-23
Hypoxic Red Blood Cells for Burns and Hematological Malignancies at Haukeland University Hospital
Hemanext
Completed
NCT04827446 2025-07-09
Lighting Intervention for Cancer-related Fatigue
University of Michigan Rogel Cancer Center
Phase NA Completed
NCT04035447 2025-06-29
Symptom Management for YA Cancer Survivors
Duke University
Phase NA Completed
NCT02791737 2025-06-13
Exercise Prehab in Older Adults With Hematologic Malignancies
Ohio State University Comprehensive Cancer Center
Phase NA Completed
NCT02988466 2025-05-28
Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT02329847 2025-05-25
A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies
Janssen Research & Development, LLC
Phase 1/2 Completed
NCT03080883 2025-05-18
Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy
Academic and Community Cancer Research United
Phase 3 Completed
NCT03149055 2025-05-16
Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT)
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00429143 2025-05-04
A Two-Step Approach to Bone Marrow Transplant Using Cells From A Partially-Matched Relative
Thomas Jefferson University
Phase 1/2 Completed
NCT01162096 2025-04-30
Reduced Intensity Haploidentical Transplant for Hematological Malignancies
Thomas Jefferson University
Phase 1/2 Completed
NCT01341301 2025-04-30
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies
Thomas Jefferson University
Phase 2 Completed
NCT01982682 2025-04-30
Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor
Thomas Jefferson University
Phase 2 Completed
NCT02717507 2025-04-23
Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors
Children's Oncology Group
Phase 2 Completed
NCT02396134 2025-03-03
Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
City of Hope Medical Center
Phase 2 Completed
NCT02038777 2025-02-26
A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies
Pfizer
Phase 1 Completed
NCT04537715 2025-02-19
Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels
Ipsen
Phase 1 Completed
NCT03125070 2025-01-29
INSPIRE
Fred Hutchinson Cancer Center
Phase 3 Completed
NCT02116530 2025-01-28
Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT04432506 2025-01-28
Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01902173 2025-01-14
Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT05061095 2024-12-27
Understanding What Matters Most to Patients: Establishing the Validity of a Best-Worst Scaling Survey
UNC Lineberger Comprehensive Cancer Center
Completed
NCT05148806 2024-12-09
MELODY
Imperial College London
Completed
NCT02880293 2024-12-06
Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor
Memorial Sloan Kettering Cancer Center
Phase NA Completed
NCT01919619 2024-12-03
Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04736056 2024-12-02
Mindfulness and CBT for Sleep
Duke University
Phase NA Completed
NCT01084252 2024-11-01
Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies
Sanofi
Phase 1/2 Completed
NCT01915498 2024-10-22
Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation
Celgene
Phase 1/2 Completed
NCT01503515 2024-10-16
Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant
Children's Oncology Group
Phase 3 Completed
NCT03823651 2024-09-27
A Research Program Targeting Pre- and Peri-transplant Optimization Program (R-PPOP)
Duke University
Phase NA Completed
NCT04847050 2024-08-27
A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT05147311 2024-07-30
PATH-3
Brigham and Women's Hospital
Phase NA Completed
NCT01664910 2024-07-23
CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Completed